Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses (NCT01948817) | Novartis Pharmaceuticals | 2014-02-01 |
Track Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD automatically
Every clearance here is in the API, with alerts when new ones post.